All Dr Eleni Lagkadinou (Vice President of Oncology Early Development at AbbVie) articles
-
ArticleHow dual-targeting ADCs aim to tackle resistance
Find out how dual-target ADCs and tumour-specific Treg depletion are shaping the next wave of targeted cancer therapies.